Immunotherapeutic strategies for the treatment of malignant melanoma.
The incidence of cutaneous malignant melanoma is increasing at a faster rate than any other cancer worldwide. Despite new advances in surgical management of melanoma, this malignancy remains one of the most aggressive and intractable to treat among other solid tumors. Continuous search for better therapeutics led to the development of various immunological approaches applicable to the treatment of this melanocytic malignancy. Multiple peptide, dendritic cell, adjuvant, lymphocyte, and virus-based strategies were established and tested in preclinical and clinical studies with varying degrees of clinical success. However, the most recent investigations in melanoma immunotherapy have clearly demonstrated that complex vaccines and the combination of different approaches, such as the use of dendritic cell vaccines in conjunction with costimulatory molecules, are superior to conventional immunization protocols in induction of tumor-specific immune responses. These recent studies open new perspectives for the development of efficient melanoma immunotherapeutics suitable for the treatment of primary and metastatic disease.
Alexeev
V
V
Department of Dermatology and Cutaneous Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. vitali.alexeev@jefferson.edu
Mucci
T
T
Igoucheva
O
O
D018925:Chemokines / Q000627:therapeutic use; D004247:DNA / Q000627:therapeutic use; D003713:Dendritic Cells / Q000637:transplantation; D006801:Humans; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000502:physiology; D014612:Vaccines / Q000627:therapeutic use*
D018925:Chemokines; D010455:Peptides; D014612:Vaccines; D004247:DNA